Top advisers to Robert F. Kennedy Jr. are battling over how aggressively to target vaccines during his first days as the ...

Merck's blockbuster drug Keytruda and Eisai's cancer drug Lenvima, in combination with chemotherapy, failed to improve ...

A recent health news roundup explores legal, financial, and strategic developments. Highlights include Robert F. Kennedy ...

The Trump administration has withdrawn a plan to ban menthol cigarettes in the U.S., in a setback to health regulators and ...

A debate over the program for skilled foreign workers has pitted immigration hard-liners against some of President Trump’s ...

The Direct File system will be open to millions of taxpayers in 25 states, up from 12 last year. But it’s unclear what will ...

The Host Julie Rovner KFF Health News @jrovner Read Julie's stories. Julie Rovner is chief Washington correspondent and host of KFF Health News’ weekly health policy news podcast, “What the Health?” A ...

Diversity, equity and inclusion programs have come under attack in American boardrooms, state legislatures and college ...

Merck (MRK) and Eisai (ESAIY) announced results from the Phase 3 LEAP-015 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, ...

Novo Nordisk (NVO) has reportedly been criticized by a U.K. pharma industry group for mischaracterizing certain payments to ...

He may have been only a virtual attendee, but the lines to see Donald J. Trump address the World Economic Forum stretched ...

Ascentage Pharma Group (AAPG) (AAPGV) (ASPHF), which is backed by Takeda (TAK), has priced a $126M U.S. initial public offering. Read more here.